In contrast, for patients with mid-to-late-stage MASLD characterized by heightened de novo lipogenesis (DNL), where intervention may be delayed, high-dose QHD can be administered to specifically inhibit key pathways such as Caspase-2/SREBP1 and JAK2/STAT3. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.